Proceedings · Session S-313 · filed November 20, 2026

Translational ScienceSession paper

55% of Mice Stayed Diabetes-Free After Hydrogel-Delivered iPSC Vesicles

UCLA researchers delivered iPSC-derived extracellular vesicles in a hyaluronic-acid hydrogel; 55% of mice remained diabetes-free after 90 days, with human efficacy still unknown.

By Tom Whitfield5 min read974 words

Summary

  • 55% of hydrogel-treated mice remained diabetes-free at the 90-day endpoint.
  • Two injections of iPSC-derived vesicles significantly delayed diabetes onset versus untreated controls.
  • Suspension culture increased vesicle production 3.4-fold per million cells.
  • Immune-cell assays compared three vesicle sources using mouse and human cells.
  • The 90-day mouse study supplied no group sizes, confidence intervals or funding disclosure.
Type 1 Diabetes Delayed in Mice by Stem Cell-Derived Vesicles That Calm Immune Response
FigureType 1 Diabetes Delayed in Mice by Stem Cell-Derived Vesicles That Calm Immune Response — AI-generated

By Tom Whitfield

Fifty-five percent of mice receiving pluripotent stem cell-derived extracellular vesicles in an injectable hydrogel were still diabetes-free at the end of a 90-day UCLA study; treated animals also retained more insulin-producing pancreatic tissue and had more regulatory T cells in lymph nodes.

That result remains preclinical: it came from an antigen-specific mouse model, not a human treatment. The report gave no group sizes, confidence intervals, statistical tests or funding source, leaving the size and robustness of the 55% benefit unresolved.

In type 1 diabetes, the immune system mistakes pancreatic insulin-producing cells for foreign tissue and destroys them; insulin therapy controls glucose but does not stop the attack. UCLA’s strategy aimed to protect surviving cells by changing immune behavior, rather than replace lost cells or increase insulin alone.

Song Li, PhD, associate dean for graduate and professional education and a professor of bioengineering at the UCLA Samueli School of Engineering, served as senior and corresponding author. The team published “Pluripotent stem cell-derived extracellular vesicles for systemic immune modulation in diabetes therapy” in Nature Nanotechnology, DOI 10.1038/s41565-026-02320-z.

Li also belongs to the UCLA Broad Stem Cell Research Center, UCLA Health Jonsson Comprehensive Cancer Center and California NanoSystems Institute.

Pregnancy supplied the biological model: a mother’s immune system generally tolerates a developing embryo even though it carries paternal genetic material. Li said: “Nature has designed something amazing. If we can better understand how an embryo avoids rejection by the mother’s immune system, it could be very useful for a lot of immune-related diseases.”

What did the experiments show?

Extracellular vesicles are tiny particles released naturally by nearly all cell types to communicate. The team tested vesicles from embryonic stem cells and induced pluripotent stem cells, or iPSCs, both pluripotent stem-cell classes with early-embryo-like characteristics. It compared them with mesenchymal stem-cell vesicles, a class already studied widely for inflammation regulation and regenerative potential.

In experiments using mouse and human immune cells, vesicles from both pluripotent classes produced stronger anti-inflammatory effects than mesenchymal stem-cell vesicles across three reported measures:

  • Proinflammatory cytokine secretion fell more strongly.
  • T-cell activation decreased.
  • Regulatory T-cell induction increased.

Further analysis found distinct proteins, lipids and genetic material in pluripotent stem-cell vesicles. Their cargo included the pluripotency-associated proteins ROR1 and CD133 and members of the miR-302 family of microRNAs, all described as absent from mesenchymal stem-cell vesicles. The report did not identify a single cargo component as necessary for the immune effect.

The team then tested the concept in an antigen-specific mouse model of type 1 diabetes. It introduced immune cells that attack insulin-producing pancreatic cells, then administered iPSC-derived vesicles either without a carrier or through the hydrogel.

How did the hydrogel change delivery?

Because soluble vesicles cleared rapidly from subcutaneous tissue, the team formulated an injectable hydrogel from hyaluronic acid and Pluronic F127 that changes from a solution to a gel at body temperature. The formulation released vesicles gradually over several days. The team cited both polymers’ wide biomedical use as support for translational potential, although the report gave no EV count per injection, quantitative release rate or cost per treatment.

Researchers injected the treatment beneath the skin near the neck, where vesicles could meet immune cells in draining lymph nodes; those cells could then circulate and potentially reduce harmful immune activity in the pancreas. The regimen used two local injections. The researchers reported that free vesicles and hydrogel-delivered vesicles each significantly delayed diabetes onset against untreated controls.

At day 90, 55% of the hydrogel-treated mice remained diabetes-free. Those mice also had more regulatory T cells in lymph nodes and retained more insulin-producing tissue, or β-cell mass, than controls. Li said: “One thing that surprised us was that a local injection could provide protection throughout the body. That’s the beauty of this approach.”

Can the vesicles be made at scale?

Consistent, high-volume production remained the next manufacturing problem. Instead of growing pluripotent stem cells on flat laboratory surfaces, the team grew them as three-dimensional aggregates suspended in gently moving liquid. Suspension culture maintained pluripotency without differentiation into embryoid bodies and increased vesicle output 3.4-fold per million cells while preserving important particle characteristics.

The team argued that iPSCs could multiply extensively in the laboratory, making them a more consistent and scalable source than adult stem cells with more limited growth potential. The 3.4-fold gain addresses the quantity bottleneck the authors named, but the report provided no per-dose cost, purification yield, potency specification or batch-to-batch variance.

What could this mean for patients?

Human safety and efficacy remain unknown. Li sees the strongest case in early-stage type 1 diabetes, when some insulin-producing cells remain functional; his rationale is that regulating immune cells may keep those cells working. Immune regulation alone cannot replace cells already lost in advanced disease, although the approach could potentially prevent immune rejection of transplanted insulin-producing cells.

Before any human study, the group plans larger-animal work on appropriate dosing, long-term effectiveness and whether the treatment weakens defenses against infection. The reported mouse experiment did not settle those questions or establish effectiveness in people.

Beyond diabetes, the authors framed pluripotent stem-cell vesicles as a possible platform for other autoimmune diseases and immune tolerance in cell therapy. Those remain preclinical hypotheses: the 90-day survival result came from one induced mouse model, and the report contains no efficacy data from human patients.

For R&D managers, the next gate is larger-animal efficacy and dosing data, alongside tests of long-term protection and infection risk; until those results arrive, 55% is a mouse-model survival figure, not a human efficacy estimate.

via doi.org (Original)

Filed under

  • induced-pluripotent-stem-cells
  • extracellular-vesicles
  • type-1-diabetes
  • hydrogel-drug-delivery
  • immune-modulation
Share this article:

More from Tom Whitfield

Tom Whitfield

Show full bio

Senior reporter covering technology and product news in research and development at Hypothesis Wire.

280 articles

References

  1. 20-Micron Hydrogel Cloak Keeps Transplanted Islets Alive 100 Days
  2. ETH Zurich implant clears glucose via electrocatalysis, no drugs
  3. Wireless Implant Restored Normal Glucose in Diabetic Mice Within an Hour
  4. USC Study Rewrites Rules of Human Blood Stem Cell Regeneration
  5. DUSP4 protein keeps CAR-T cells killing colorectal tumours, NUS study finds

« Previous article